Probiotics for Weight Loss

Not Applicable

Completed

• Conditions: Overweight
• Interventions: Dietary Supplement: LB001

• Registration Number: NCT04897698
• Lead Sponsor: Karolinska Institutet

Brief Summary

This study will investigate a compound of probiotics and prebiotics in females and males with overweight with the aim to evaluate the effect on weight and metabolic markers.

The design is a three month randomized doubled-blinded, three-armed placebo-controlled trial of probiotics for weight loss. Normal dose (2 capsules á 0.4g per day) doubled dose (4 capsules á 0.4g per day), or placebo.

A second, non-blinded, phase with only the compound of probiotics and prebiotics, with tripple dose (6 capsuled á 0.4g per day), will be performed for individuals who had the compound in the first phase.

Detailed Description

Participants Total number of study participants will be 75-90, consisting of overweight men and women, 18-45 years of age.

Treatment Dietary supplement consisting of probiotic capsules called LB001. It contains strains of pediococcus (Bacterial family of Lactobacillaceae) and saccharomycetes (kingdom of Fungi and the division Ascomycota) with a concentration of 13 millions cfu/g. Other ingredients (including stabilization) include rice bran, vegetable L-Cystein, magnesium salts from vegetable fatty acids. The capsule shell is made of vegetable HydroxyPropylMetylCellulosa (HPMC). Each capsule has a weight of 0.4 gram. The placebo is made of rice flour.

Since one of the inclusion criteria is "willingness to lose weight", all study participants, regardless of randomized treatment, will receive general advice regarding healthy lifestyle habits.

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study First Submitted: 2021-05-18
• Study First Submitted QC: 2021-05-18
• Study First Posted: 2021-05-21
• Study Start: 2021-10-16
• Primary Completion: 2022-05-09
• Study Completion: 2022-05-09
• Status Verified: 2023-03
• Last Update Submitted: 2023-03-07
• Last Update Posted: 2023-03-08

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 81

Inclusion Criteria

• BMI 26.0 - 29,99 kg/m2
• 18-45 years old
• Willingness to lose weight

Read More

Exclusion Criteria

• Active weight loss in the last three months
• The desire for or planned pregnancy upcoming months
• Chronic somatic diseases that may affect metabolic and/or intestinal function (e.g. diabetes, hypertension, dyslipidemia, Irritable Bowel Disorder (IBD), gluten intolerance, pancreatic dysfunction, other causes of malabsorption, neoplastic disease)
• Allergies with previous anaphylactic reactions
• Abdominal surgery six months prior to inclusion
• Current or history of eating disorders
• Extreme or unusual diets for the last three months, which the investigator considers could negatively affect the outcome of the study
• Psychiatric disorders (e.g., schizophrenia, and other diagnoses that may influence compliance)
• Drug or alcohol abuse
• Continuous oral pharmacological treatment and other types of pharmacological treatment that may influence the study
• Present or recent usage of other probiotic agents
• Other conditions which the investigator considers could negatively affect the outcome of the study or study compliance

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: FACTORIAL

Arm && Interventions

Group	Intervention	Description
Single dose	LB001	Two capsules of probiotics and two capsules of placebo daily. Probiotic capsules contains strains of pediococcus (Bacterial family of Lactobacillaceae) and saccharomycetes (kingdom of Fungi and the division Ascomycota) with a concentration of 13 millions cfu/g. Other ingredients (including stabilization) include rice bran, vegetable L-Cystein, magnesium salts from vegetable fatty acids. The capsule shell is made of vegetable HydroxyPropylMetylCellulosa (HPMC). Each capsule has a weight of 0.4 gram. The placebo is made of rice flour.
Double dose	LB001	Four capsules of probiotics daily. Probiotic capsules contains strains of pediococcus (Bacterial family of Lactobacillaceae) and saccharomycetes (kingdom of Fungi and the division Ascomycota) with a concentration of 13 millions cfu/g. Other ingredients (including stabilization) include rice bran, vegetable L-Cystein, magnesium salts from vegetable fatty acids. The capsule shell is made of vegetable HydroxyPropylMetylCellulosa (HPMC). Each capsule has a weight of 0.4 gram.
Placebo	LB001	Four capsules containing rice flour will be given to the placebo group daily.

Primary Outcome Measures

Name	Time	Method
Weight change	Baseline, 6-month follow-up	Weight will be measured in kilograms using a scale.

Secondary Outcome Measures

Name	Time	Method
Waist circumference	Baseline, 6-month follow-up	Participants waist circumference will be measured using a standard tape measure (in cm).
HDL	Baseline, 6-month follow-up	High-density lipoproteins will be measured in plasma (mmol/L)
Triglycerides	Baseline, 9-month follow-up	Triglycerides will be measured in plasma (mmol/L)
HbA1c	Baseline, 6-month follow-up	Glycated hemoglobin A1c will be measured in blood (mmol/mol)

Trial Locations

Locations (1)

Karolinska Institutet, Department of Clinical Science, Intervention and Technology; 🇸🇪 Huddinge, Stockholm, Sweden